Rivastigmine is a reversible cholinesterase inhibitor used to manage cognitive impairment and dementia associated with Alzheimer's disease and Parkinson's disease. As a therapeutic agent, its quality relies… Read more
![Chemical structure of Rivastigmine Related Compound B ((R,S)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate) (1604870)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F25081-93-0-Rivastigmine-Related-Compound-B-RS-3-1-Dimethylaminoethylphenyl-dimethylcarbamate-1604870.png&w=3840&q=75)
![Chemical structure of Rivastigmine Related Compound E ((S)-1-(3-{[Ethyl(methyl)carbamoyl]oxy}phenyl)-N,N,N-trimethylethan (1604950)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FRivastigmine-Related-Compound-E-S-1-3-Ethylmethylcarbamoyloxyphenyl-NNN-trimethylethan-1604950.png&w=3840&q=75)









Rivastigmine is a reversible cholinesterase inhibitor used to manage cognitive impairment and dementia associated with Alzheimer's disease and Parkinson's disease. As a therapeutic agent, its quality relies on precise analytical monitoring throughout the drug development and manufacturing lifecycle. This category provides comprehensive reference standards of the active ingredient, along with a broad range of related compounds, including synthetic impurities, degradation products, and metabolites. These materials are essential for accurate impurity profiling, method validation, and rigorous pharmaceutical quality control. Additionally, this catalogue includes stable isotope labelled versions of the drug and its related substances, which are required as internal standards for reliable quantification in sensitive analytical techniques such as liquid chromatography-mass spectrometry. By utilizing these specialized reference materials, laboratories can ensure the necessary consistency, safety, and regulatory compliance required for pharmaceutical research and routine analytical testing.